Inventor · disambiguated record
Jonathan Bentley
Also filed as: BENTLEY JONATHAN · BENTLEY JONATHAN M · BENTLEY JONATHAN MARK
25 granted patents·13 pending applications·227 citations·filing 1999–2024
95Inventor score
Files withVERNALIS RES LTD10DISARM THERAPEUTICS INC7HOFFMANN LA ROCHE5NAVITOR PHARM INC3UCB BIOPHARMA SPRL3
Top patents by PatentIndex Score
38 records- 0193US6706750B1Indole derivatives process for their preparation, pharmaceutical compositions containing them and their medicinal applicationVERNALIS RES LTD·Filed 2000·Granted Mar 16, 2004·68 cites·23 claims
- 0287US9868749B2Fused imidazole and pyrazole derivatives as modulators of TNF activityUCB BIOPHARMA SPRL·Filed 2014·Granted Jan 16, 2018·16 cites·7 claims
- 0382US6479534B1Indoline derivatives and method of treating obesityHOFFMANN LA ROCHE·Filed 2001·Granted Nov 12, 2002·19 cites·32 claims
- 0481US7253281B2Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indolesVERNALIS RES LTD·Filed 2005·Granted Aug 7, 2007·3 cites·8 claims
- 0577US6583134B2Aza- indolyl derivatives for treating obesityHOFFMANN LA ROCHE·Filed 2001·Granted Jun 24, 2003·10 cites·31 claims
- 0676US10414727B2Phenyl amino piperidine mTORC inhibitors and uses thereofNAVITOR PHARM INC·Filed 2017·Granted Sep 17, 2019·1 cites·17 claims
- 0775US9309243B2Imidazopyridine derivatives as modulators of TNF activityUCB BIOPHARMA SPRL·Filed 2013·Granted Apr 12, 2016·4 cites·11 claims
- 0875US6610685B2Fused indole derivativesHOFFMANN LA ROCHE·Filed 2001·Granted Aug 26, 2003·11 cites·47 claims
- 0974US9475820B2Substituted imidazo[1,2-a]pyrazines as TNF activity modulatorsUCB BIOPHARMA SPRL·Filed 2013·Granted Oct 25, 2016·3 cites·14 claims
- 1073US6933387B2Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indolesVERNALIS RES LTD·Filed 2003·Granted Aug 23, 2005·4 cites·24 claims
- 1172US6433175B1Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonistsVERNALIS RES LTD·Filed 1999·Granted Aug 13, 2002·32 cites·27 claims
- 1271US12162895B2DNA polymerase theta inhibitor for treatment of cancerBREAKPOINT THERAPEUTICS GMBH·Filed 2024·Granted Dec 10, 2024·0 cites·6 claims
- 1371US12145945B2Compounds, compositions, and therapeutic uses thereofBREAKPOINT THERAPEUTICS GMBH·Filed 2024·Granted Nov 19, 2024·0 cites·4 claims
- 1469US7323466B2Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesityHOFFMANN LA ROCHE·Filed 2006·Granted Jan 29, 2008·1 cites·14 claims
- 1568US6380238B1Indoline derivatives as 5-HT2B and or 5-HTC receptor ligandsVERNALIS RES LTD·Filed 1999·Granted Apr 30, 2002·27 cites·23 claims
- 1662US10844013B2Phenyl amino piperidine mTORC inhibitors and uses thereofNAVITOR PHARM INC·Filed 2019·Granted Nov 24, 2020·0 cites·18 claims
- 1760US12331033B2Inhibitors of SARM1DISARM THERAPEUTICS INC·Filed 2021·Granted Jun 17, 2025·0 cites·6 claims
- 1860US2007106076A1Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indolesBENTLEY JONATHAN M·Filed 2007·Application pending·0 cites
- 1958US12448374B2Inhibitors of SARM1DISARM THERAPEUTICS INC·Filed 2019·Granted Oct 21, 2025·0 cites·2 claims
- 2057US6365598B1Pyrroloquinolines for treatment of obesityVERNALIS RES LTD·Filed 1999·Granted Apr 2, 2002·15 cites·29 claims
- 2156US6552062B1Indazole derivatives with 5-HT2 receptor activityVERNALIS RES LTD·Filed 1999·Granted Apr 22, 2003·13 cites·24 claims
- 2255US12435084B2Indazole derivatives as inhibitors of SARM1DISARM THERAPEUTICS INC·Filed 2021·Granted Oct 7, 2025·0 cites·10 claims
- 2355US2009181939A1Azetidinecarboxamide Derivatives And Their Use In The Treatment Of CB1 Receptor Mediated DisordersVERNALIS RES LTD·Filed 2009·Application pending·0 cites
- 2454US12441719B2Inhibitors of SARM1DISARM THERAPEUTICS INC·Filed 2020·Granted Oct 14, 2025·0 cites·10 claims
- 2552US12338238B2Inhibitors of SARM1DISARM THERAPEUTICS INC·Filed 2019·Granted Jun 24, 2025·0 cites·16 claims
- 2652US7022707B2Piperazine derivativesHOFFMANN LA ROCHE·Filed 2004·Granted Apr 4, 2006·0 cites·43 claims
- 2752US2009042897A1Chemical CompoundsGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 2851US2002035110A1Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indolesFiled 2001·Application pending·0 cites
- 2949US2007173486A1Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disordrsVERNALIS RES LTD·Filed 2004·Application pending·0 cites
- 3048US2022242859A1Inhibitors of sarm1DISARM THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3147US2010286151A11-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating DisordersBENTLEY JONATHAN·Filed 2008·Application pending·0 cites
- 3245US2002143020A1Novel piperazine derivativesFiled 2001·Application pending·0 cites
- 3343US7098337B21,2,3,4,9,9a-hexahydro-2,4a,5-triaza-fluorene and 1,2,3,4-tetrahydro-2,4a,5-triaza-fluorene derivativesVERNALIS RES LTD·Filed 2003·Granted Aug 29, 2006·0 cites·34 claims
- 3443US2021261537A1Inhibitors of sarm1DISARM THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3541US2010197699A1I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating DisordersGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 3640US2010216821A1Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 AntagonistsBARTON NICHOLAS PAUL·Filed 2008·Application pending·0 cites
- 3739US2019389843A1PYRROLE mTORC INHIBITORS AND USES THEREOFNAVITOR PHARM INC·Filed 2017·Application pending·0 cites
- 3836US2012022056A1Fused tricyclic derivatives for the treatment of psychotic disordersBENTLEY JONATHAN·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan Bentley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →